



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	353310	LiviUP
ARTG entry for	Medicine Listed	
Sponsor	iX Biopharma Pty Ltd	
Postal Address	110 Merrindale Drive, Croydon, VIC, 3136 Australia	
ARTG Start Date	19/01/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . LiviUP

Product Type	Single Medicine Product	Effective Date	19/01/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support general health and wellbeing
Maintain/support liver health

Indication Requirements

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. Not recommended for use by pregnant and lactating women (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral

Visual Identification

Active Ingredients

Hovenia dulcis fruit Extract dry concentrate	250 mg
--	--------



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Equivalent: Hovenia dulcis (Dry)	11.25 g
Silybum marianum fruit Extract dry concentrate	50 mg
Equivalent: Silybum marianum (Dry)	3.5 g
thiamine hydrochloride	20 mg

Other Ingredients (Excipients)

brilliant blue FCF

Gelatin

magnesium stearate

microcrystalline cellulose

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary